Crizotinib: A comprehensive profile

Publication type: Book Chapter
Publication date: 2023-02-02
Elsevier
SJR: —
CiteScore: 18.2
Impact factor: —
ISSN: 18715125, 00995428
Abstract
Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.
Found 
Found 

Top-30

Journals

1
Toxicology and Applied Pharmacology
Toxicology and Applied Pharmacology, 1, 16.67%
Toxicology and Applied Pharmacology
1 publication, 16.67%
Biomedicines
Biomedicines, 1, 16.67%
Biomedicines
1 publication, 16.67%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 1, 16.67%
Bioorganic and Medicinal Chemistry Letters
1 publication, 16.67%
Oncology Letters
Oncology Letters, 1, 16.67%
Oncology Letters
1 publication, 16.67%
Frontiers in Immunology
Frontiers in Immunology, 1, 16.67%
Frontiers in Immunology
1 publication, 16.67%
1

Publishers

1
2
Elsevier
Elsevier, 2, 33.33%
Elsevier
2 publications, 33.33%
MDPI
MDPI, 1, 16.67%
MDPI
1 publication, 16.67%
Wiley
Wiley, 1, 16.67%
Wiley
1 publication, 16.67%
Spandidos Publications
Spandidos Publications, 1, 16.67%
Spandidos Publications
1 publication, 16.67%
Frontiers Media S.A.
Frontiers Media S.A., 1, 16.67%
Frontiers Media S.A.
1 publication, 16.67%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Share
Cite this
GOST |
Cite this
GOST Copy
Abdelgalil A. A., Alkahtani H. M. Crizotinib: A comprehensive profile // Profiles of Drug Substances, Excipients and Related Methodology. 2023. Vol. 48. pp. 39-69.
GOST all authors (up to 50) Copy
Abdelgalil A. A., Alkahtani H. M. Crizotinib: A comprehensive profile // Profiles of Drug Substances, Excipients and Related Methodology. 2023. Vol. 48. pp. 39-69.
RIS |
Cite this
RIS Copy
TY - GENERIC
DO - 10.1016/bs.podrm.2022.11.002
UR - https://doi.org/10.1016/bs.podrm.2022.11.002
TI - Crizotinib: A comprehensive profile
T2 - Profiles of Drug Substances, Excipients and Related Methodology
AU - Abdelgalil, Ahmed A
AU - Alkahtani, Hamad M.
PY - 2023
DA - 2023/02/02
PB - Elsevier
SP - 39-69
VL - 48
PMID - 37061275
SN - 1871-5125
SN - 0099-5428
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@incollection{2023_Abdelgalil,
author = {Ahmed A Abdelgalil and Hamad M. Alkahtani},
title = {Crizotinib: A comprehensive profile},
publisher = {Elsevier},
year = {2023},
volume = {48},
pages = {39--69},
month = {feb}
}